This site is intended for healthcare professionals only
LoginRegister
Sanofi DupixentGlooko, Sanofi collaborate for SoloStar Pen Connectivity with New Device SoloSmart
Gilead Sciences Kite completes acquisition of TmunityGilead Sciences' Kite completes acquisition of Tmunity
Lupin Partners with TB Alliance to Advance Telacebec for TB, Leprosy and Buruli UlcerAstraZeneca enters license agreement with KYM Biosciences for CMG901
Eli Lilly Gets CDSCO Panel Nod To Import, Market Lasmiditan for acute treatment of migraineEli Lilly Gets CDSCO Panel Nod To Import, Market Lasmiditan for acute treatment of migraine
Pharmacy college Principal set on fire by former student succumbs to injuriesPharmacy college Principal set on fire by former student succumbs to injuries
Rick Suarez Named Head of AstraZenecas US Biopharma Business Amid USD 50 Billion Expansion PlanAstraZeneca-Daiichi Sankyo Enhertu approved in China for breast cancer
USFDA nod to Padcev plus Keytruda for certain patients with Bladder cancer: Pfizer, Astellas PharmaPfizer, BioNTech seek USFDA nod for Omicron BA.4/BA.5-Adapted Bivalent COVID vaccine for ages 12...
USFDA nod to Zydus Lifesciences Pitavastatin TabletsUSFDA nod to Zydus Lifesciences Pitavastatin Tablets
Imfinzi plus Imjudo approved in EU for patients with advanced liver and non small cell lung cancers: AstraZenecaImfinzi plus Imjudo approved in EU for patients with advanced liver and non small cell lung cancers:...
Sun Pharma, Philogen complete patient enrollment in Phase III trial for Soft Tissue SarcomaSun Pharma Gets CDSCO panel nod to manufacture, market antidiabetic FDC drug
CDSCO Expert Panel Backs Akums Faropenem Dispersible Tablets, Grants CT, BE WaiversAkums Drugs and Pharma, Lyrus Life Sciences ink pact for development of patented technologies
USFDA grants priority review to Pfizer Elranatamab for relapsed or refractory multiple myelomaUSFDA grants priority review to Pfizer Elranatamab for relapsed or refractory multiple myeloma
X